SCHEMBL1500161

SCHEMBL1500161

CC1(C)Cc2cc(Br)ccc2C1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 1/20 0.46
METAP1 P53582 2/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA4 P22748 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
PARP10 Q53GL7 1/20 0.42
PARP11 Q9NR21 1/20 0.42
S100A4 P26447 1/20 0.41
BRD4 O60885 1/20 0.40
SRD5A1 P18405 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
GRM1 Q13255 1/20 0.38
SRD5A2 P31213 1/20 0.38
MALT1 Q9UDY8 1/20 0.37
CMA1 P23946 1/20 0.37
AHR P35869 1/20 0.37
PDE4B Q07343 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1572850 0.85 TDP1 (0.46) TDP2METAP1CA1CA2CA4
SCHEMBL30676574 0.85 TDP1 (0.46) TDP2METAP1CA1CA2CA4
SCHEMBL9588334 0.82 PARP10 (0.47) TDP2METAP1CA1CA2CA4
SCHEMBL1500165 0.80 TDP2 (0.41) TDP2METAP1CA1CA2CA4
SCHEMBL12310527 0.79 METAP1 (0.44) METAP1CA1CA2CA4CA7
SCHEMBL28355091 0.79 TDP2 (0.47) TDP2METAP1CA1CA2CA4
SCHEMBL20950906 0.78 CASP1 (0.47) TDP2CA9S100A4TDP1GRM1
SCHEMBL20951823 0.78 TDP2 (0.46) TDP2METAP1CA1CA2CA4
SCHEMBL20951663 0.78 CA1 (0.43) TDP2CA1CA2CA7CA9
SCHEMBL3959283 0.78 ESR2 (0.51) CA1CA2CA7CA9ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260146035-A1 FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS DONG-A ST CO., LTD. (KR) 2026-05-28 US disclosed
US-12522602-B2 Derivatives having 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same YUHAN CORPORATION (KR) 2026-01-13 US disclosed
EP-4663630-A1 NOVEL BENZIMIDAZOLONE DERIVATIVE COMPOUND AS AUTOTAXIN INHIBITOR LG Chem, Ltd. (KR) 2025-12-17 EP disclosed
EP-4389744-B1 DERIVATIVES HAVING 2,3-DIHYDRO-1H-INDENE OR 2,3-DIHYDROBENZOFURAN MOIETY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORP (KR) 2025-12-03 EP disclosed
EP-4608828-A1 IMPROVED PROCESSES FOR PREPARING DIMETHYL-2,3-DIHYDRO-1H-INDENE DERIVATIVES Yuhan Corporation (KR) 2025-09-03 EP disclosed
EP-4605395-A2 FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS Dong-A ST Co., Ltd. (KR) 2025-08-27 EP disclosed
CN-119923397-A Improved process for preparing dimethyl-2, 3-dihydro-1H-indene derivatives 柳韩洋行 2025-05-02 CN disclosed
CN-113631168-B GPR35 modulators 普罗米修斯生物科学公司 2024-11-19 CN disclosed
CN-118955495-A Derivatives having 2, 3-dihydro-1H-indene or 2, 3-dihydrobenzofuran moiety or pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the same 柳韩洋行 2024-11-15 CN disclosed
CN-115151252-B Iron death inhibitor-diarylamine acetamides 维泰瑞隆有限公司 2024-08-27 CN disclosed
US-20070173507-A1 Dairyl-substituted five-membered heterocycle derivative MSD K.K. (JP) 2007-07-26 US disclosed
CN-1934094-A Diaryl substituted heterocyclic 5-membered ring derivatives BANYU PHARMA CO LTD (JP) 2007-03-21 CN disclosed
WO-2007000340-A2 BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS PALAU PHARMA, S.A. (ES) 2007-01-04 WO disclosed
WO-2007000337-A1 BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS PALAU PHARMA, S.A. (ES) 2007-01-04 WO disclosed
WO-2007000339-A1 BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS PALAU PHARMA, S.A. (ES) 2007-01-04 WO disclosed
EP-1726585-A1 DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-29 EP disclosed
EP-0968168-B1 AROMATIC TETRACYCLIC COMPOUNDS OF THE RETINOID TYPE, METHOD FOR PREPARING AND USE CT EUROP DE BIOPROSPECTIVE CEB (FR) 2001-08-29 EP disclosed
US-6239284-B1 SKIN DISORDERS; ANTICANCER AGENTS CENTRE EUROPEEN DE BIOPROSPECTIVE-CEB (FR) 2001-05-29 US disclosed
EP-0968168-A1 AROMATIC TETRACYCLIC COMPOUNDS OF THE RETINOID TYPE, METHOD FOR PREPARING AND USE Centre Europeen de Bioprospective -CEB (FR) 2000-01-05 EP disclosed
WO-1998031654-A1 AROMATIC TETRACYCLIC COMPOUNDS OF THE RETINOID TYPE, METHOD FOR PREPARING AND USE CENTRE EUROPEEN DE BIOPROSPECTIVE -CEB- (FR) 1998-07-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173507-A1 Dairyl-substituted five-membered heterocycle derivative OPRK1, OPRL1, GRM1 TDP2 4437/4885METAP1 2781/4885CA1 1340/4885
US-20260146035-A1 FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS AXL, ERBB2, ERBB3 TDP2 4189/4885METAP1 989/4885CA1 1107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.